SHR-A2102 plus adebrelimab versus platinum-based chemotherapy for advanced urothelial carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial compares a combination therapy of SHR-A2102 and the anti–PD-L1 antibody adebrelimab against standard platinum-based chemotherapy (gemcitabine with cisplatin or carboplatin) in patients with untreated locally advanced or metastatic urothelial carcinoma. Eligible participants must have measurable disease, be cisplatin- or carboplatin-tolerant, have ECOG performance status 0–1, and provide tumor tissue for Nectin-4 and PD-L1 testing. The trial is sponsored by Suzhou Suncadia Biopharmaceuticals and is being conducted at Beijing Cancer Hospital. The primary focus is on clinical benefit with biomarker collection to explore response predictors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be able to sign the informed consent form in writing.
2. Female or male, 18 to 80 years of age (both inclusive).
3. ECOG performance status of 0 or 1.
4. Expected survival of≥ 3 months.
5. Histologically confirmed diagnosis of urothelial carcinoma with radiographic or other confirmation of locally advanced unresectable or metastatic disease.
6. No prior systemic therapy for locally advanced or metastatic disease.
7. Able to provide archived or fresh tumor tissue for Nectin-4 and PD-L1 expression.
8. According to RECIST v1.1, there must be at least one measurable lesion;
9. Tolerant to cisplatin or carboplatin.
10. Adequate organ functions.
11. Agree to use medically approved contraceptive measures.

Exclusion Criteria:

1. Planned to receive any other anti-tumor therapy during the study.
2. Received other investigational products or treatments not yet marketed within 4 weeks.
3. Have received systemic anti-tumor treatment within 4 weeks;have received prior anti-tumor Chinese patent medicine treatment within 2 weeks; palliative radiotherapy or local therapy within 2 weeks.
4. Previously received therapy with an antibody-drug conjugate that meets any one of the following characteristics: targeting Nectin-4; containing irinotecan or its derivatives and acting as a topoisomerase I inhibitor.
5. Prior treatment with immune checkpoint inhibitors.
6. Major surgical procedure other than diagnostic or biopsy within 4 weeks, requiring elective surgery during the trial.
7. Active autoimmune disease requiring systemic treatment within 2 years.
8. Have experienced adverse events caused by previous anti-tumor treatments that have not recovered to grade ≤1 as per NCI-CTCAE v5.0.
9. Uncontrolled central nervous system metastases or carcinomatous meningitis.
10. Subjects with clinical symptoms or serous cavity effusion requiring puncture drainage.
11. Other malignancies within 5 years.
12. History of clinically significant pulmonary disease or any such disease suggested by chest imaging at screening.
13. Serious infections requiring intravenous antibiotics, antivirals, or antifungals for control.
14. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
15. History of immunodeficiency, or history of organ transplant.
16. Have experienced arteriovenous thrombosis or cardiovascular and cerebrovascular accidents within 6 months.
17. Subjects with clinically significant hemorrhage within 3 months.
18. Glycosylated hemoglobin (HbA1c) ≥ 8%.
19. Have serious cardiovascular and cerebrovascular diseases.
20. Allergic reaction to any component of the study treatment.
21. Subjects with active pulmonary tuberculosis.
22. History of severe dry eye, active keratitis, or corneal ulcer, or other conditions.
23. Female Subjects who are pregnant or planning to become pregnant during the study.
24. Other conditions unsuitable into the study.

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Chi Zhang
• Email: chi.zhang@hengrui.com
• Phone: +8618456513908

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer

  This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886047

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

• Shrinkage-free combo in LS-SCLC: SHR-7787 plus SHR-1316

  This trial tests whether the combo of SHR-7787 and SHR-1316 can help adults with unresectable limited-stage small cell lung cancer after prior platinum-based chemo and radiation.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07798947

• Neoadjuvant therapy with adebrelimab, famitinib, and chemotherapy for resectable ESCC

  This study tests a combination of adebrelimab, famitinib, and chemotherapy before surgery in people with resectable locally advanced esophageal squamous cell carcinoma to see if it can lead to a complete tumor disappearance at the time of surgery.

  Recruiting Phase 2 First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shannxi · NCT07796113

• A combination therapy for advanced second-line gastric cancer using apatinib with albumin-bound paclitaxel, with or without adebrelimab

  This study tests whether adding adebrelimab to a regimen of apatinib and albumin-bound paclitaxel helps patients with advanced gastric or gastroesophageal junction cancer who did not respond to first-line therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07770113

• Short-course radiotherapy with Adebrelimab and platinum chemo before surgery for locally advanced cervical cancer

  This trial tests a short course of radiotherapy combined with Adebrelimab and platinum chemotherapy to shrink locally advanced cervical cancer before surgery.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07731828

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.